Randomized trial of liposomal bupivacaine on ERAS program with Larissa Meyer

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Larissa Meyer to discuss randomized trial of liposomal bupivacaine on ERAS program. Dr. Meyer is an associate professor in the Department of Gynecologic Oncology and Reproductive Medicine with a joint appointment in the Department of Health Services Research at the University of Texas MD Anderson Cancer Center. Her research focuses on patient reported outcomes, with a focus on improving quality of life and shared medical decision making. Highlights: • To minimize bias, all surgeons on the study were all trained in injection techniques prior to enrolling patients and randomization was stratified by surgeon. • The addition of liposomal bupivacaine to 0.25% bupivacaine for local wound infiltration did not improve the proportion of patients who were opioid free after laparotomy. • The addition of liposomal bupivacaine to 0.25% bupivacaine for local wound infiltration did not improve key secondary endpoints such as patient reported pain or amount of opioids taken postoperatively. Larissa Meyer (@LarissaAMeyerMD / @MDAndersonNews)